Dihydrofuro[3,4-c]pyridinones as inhibitors of the cytolytic effects of the pore-forming glycoprotein perforin

Journal of Medicinal Chemistry

Volumn 51, Issue 23, 2008, Pages 7614-7624

  Lena, Gersande ^a   Trapani, Joseph A ^b   Sutton, Vivien R ^b   Ciccone, Annette ^b   Browne, Kylie A ^b   Smyth, Mark J ^b   Denny, William A ^a   Spicer, Julie A ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDROFURO[3,4 C]PYRIDINONE; PERFORIN; PYRIDONE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; CYTOLYSIS; DRUG ACTIVITY; DRUG DESIGN; DRUG STRUCTURE; DRUG SYNTHESIS; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; LYMPHOCYTE; NATURAL KILLER CELL; STRUCTURE ACTIVITY RELATION;

ANIMALS; APOPTOSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; ERYTHROCYTES; FURANS; HUMANS; JURKAT CELLS; KILLER CELLS, NATURAL; MOLECULAR STRUCTURE; PERFORIN; PYRIDONES; SHEEP; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; THIONES;

EID: 57349090147     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm801063n     Document Type: Article

References (45)

1. Voskoboinik, I.; Smyth, M. J.; Trapani, J. A. Perforin-mediated target-cell death and immune homeostasis. Nat. Rev. Immunol. 2006, 6, 940-952.
2. Lieberman, J. Mechanisms of granule-mediated cytotoxicity. Curr. Opin. Immunol. 2003, 15, 513-515.
3. Ashton-Rickardt, P. G. The granule pathway of programmed cell death. Crit. Rev. Immunol. 2005, 25, 161-182.
4. Russell, J. H.; Ley, T. J. Lymphocyte-mediated cytotoxicity. Annu. Rev. Immunol. 2002, 20, 323-370.
5. Lichtenheld, M. G.; Olsen, K. J.; Lu, P.; Lowrey, D. M.; Hameed, A.; Hengartner, H.; Podack, E. R. Structure and function of human perforin. Nature 1988, 335, 448-451.
6. Podack, E. R. Perforin: Structure, function and regulation. Curr. Top. Microbio. Immun. 1992, 178, 175-185.
7. Trapani, J. A.; Smyth, M. J. Functional significance of the perforin/granzyme cell death pathway. Nat. Rev. Immunol. 2002, 2, 735-747.
8. Voskoboinik, I.; Trapani, J. A. Addressing the mysteries of perforin function. Immunol. Cell Biol. 2006, 84, 66-71.
9. Rosado, C. J.; Buckle, A. M.; Law, R. H. P.; Butcher, R. E.; Kan, W.-T.; Bird, C. H.; Ung, K.; Browne, K. A.; Baran, K.; Bashtannyk-Puhalovich, T. A.; Faux, N. G.; Wong, W.; Porter, C. J.; Pike, R. N.; Ellisdon, A. M.; Pearce, M. C.; Bottomley, S. P.; Emsley, J.; Smith, A. I.; Rossjohn, J.; Hartland, E. L.; Voskoboinik, I; Trapani, J. A.; Bird, P. I.; Dunstone, M. A.; Whisstock, J. C. A common fold mediates vertebrate defence and bacterial attack. Science 2007, 317, 1548-1551.
10. Kagi, D.; Ledermann, B.; Burki, K.; Seiler, P.; Odermatt, B.; Olsen, K. J.; Podack, E. J.; Zinkernagel, R. M.; Hengartner, H. Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-defficient mice. Nature 1994, 369, 31-37.
11. Kagi, D.; Odermatt, B.; Seiler, P.; Zinkernagel, R. M.; Mak, T. W.; Hengartner, H. Reduced incidence and delayed onset of diabetes in perforin-deficient nonobese diabetic mice. J. Exp. Med. 1997, 186, 989-997.
12. Katano, H.; Cohen, J. I. Perforin and lymphohistiocytic proliferative disorders. Br. J. Haematol. 2005, 128, 739-750.
13. Henter, J.-I.; Arico, M.; Elinder, G.; Imashuku, S.; Janka, G. Familial hemophagocytic lymphohistiocytosis. Primary hemophagocytic lymphohistiocytosis. Hematol. Oncol. Clin. North Am. 1998, 12, 417-433.
14. Voskoboinik, I.; Thia, M.-C.; De Bono, A.; Browne, K.; Cretney, E.; Jackson, J. T.; Darcy, P. K.; Jane, S. M.; Smyth, M. J.; Trapani, J. A. The functional basis for hemophagocytic lymphohistiocytosis in a patient with co-inherited missense mutations in the perforin (PFN1) gene. J. Exp. Med. 2004, 200, 811-816.
15. Catalfamo, M.; Henkart, P. A. Perforin and the granule exocytosis cytotoxicity pathway. Curr. Opin. Immunol. 2003, 15, 522-527.
16. Pearl-Yafe, M.; Kaminitz, A.; Yolcu, E. S.; Yaniv, I.; Stein, J.; Askenasy, N. Pancreatic islets under attack: cellular and molecular effectors. Curr. Pharm. Des. 2007, 13, 749-760.
17. Veale, J. L.; Liang, L. W.; Zhang, Q.; Gjertson, D. W.; Du, Z.; Bloomquist, E. W.; Jia, J.; Qian, L.; Wilkinson, A. H.; Danovitch, G. M.; Pham, P.-T. T.; Rosenthal, J. T.; Lassman, C. R.; Braun, J.; Reed, E. F.; Gritsch, H. A. Noninvasive diagnosis of cellular and antibody-mediated rejection by perforin and granzyme B in renal allografts. Hum. Immunol. 2006, 67, 777-786.
18. Choy, J. C.; Kerjner, A.; Wong, B. W.; McManus, B. M.; Granville, D. J. Perforin mediates endothelial cell death and resultant transplant vascular disease in cardiac allografts. Amer. J. Pathol. 2004, 165, 127-133.
19. Barry, M.; Bleackley, R. C. Cytotoxic T lymphocytes: All roads lead to death. Nature Rev. Immunol. 2002, 2, 401-109.
20. +-ATPase inhibitors on CTL-mediated cytotoxicity. Immunol. Lett. 1997, 55, 139-144.
21. Kataoka, T.; Shinohara, N.; Takayama, H.; Takaku, K.; Kondo, S.; Yonehara, S.; Nagai, K. Concanamycin A, a powerful tool for characterization and estimation of contribution of perforin- and Fas-based lytic pathways in cell-mediated cytotoxicity. J. Immunol. 1996, 156, 3678-3686.
22. Kataoka, T.; Taniguchi, M.; Yamada, A.; Suzuki, H.; Hamada, S.; Magae, J.; Nagai, K. Identification of low molecular weight probes of perforin- and Fas-based killing mediated by cytotoxic T-lymphocytes. Biosci. Biotechnol. Biochem. 1996, 60, 1726-1728.
23. Holloway, G. A.; Baell, J. B.; Fairlamb, A. H.; Novello, P. M.; Parisot, J. P.; Richardson, J.; Watson, K. G.; Street, I. P. Discovery of 2-iminobenzimidazoles as a new class of trypanothione reductase inhibitor by high-throughput screening. Bioorg. Med. Chem. Lett. 2007, 17, 1422-1427.
24. Trapani, J. A. and Smyth, M. J. Retroviral vectors encoding recombinant mouse perforin, its expression and therapeutic uses thereof. Patent WO 2005083098 A1, March. 1, 2005.
25. Kaigodorova, E. A.; Kvak, S. N.; Ugrak, B. I.; Zaplishnyi, V. N.; Kul'nevich, V. G. Studies of furopyridines. VI. Synthesis and steric structure of hetarylmethylene-4-thiofuro[3,4-c]pyridin-3-ones. Russ. J. Org. Chem. 1995, 31, 1650-1652.
26. Kaigorodova, E. A.; Mikhailichenko, S. N.; Vasilin, V. K.; Terekhov, V. I.; Kul'nevich, V G. Investigation of furopyridines. Part 7. Synthesis and antibacterial activity of 1-arylidene-3-oxo-4-thioxofuro[3,4-c]- pyridines. Pharm. Chem. J. 1998, 32, 194-196.
27. Arustamova, I. S.; Kaigorodova, E. A.; Kul'nevich, V. G.; Ugrak, B. I. Research in the field of furopyridines. 2. Synthesis and steric structure of 6-methyl-1-hetarylidene-3,4-dioxo[3,4-c]pyridines. Chem. Heterocycl. Compds. 1993, 29, 539-544.
28. Bruce, W. F.; Coover, H. W. Pyridine Derivatives. I. 3-Cyano-4- ethoxymethyl-6-methyl-2-pyridone and some related transformation products. J. Am. Chem. Soc. 1944, 66, 2092-2094.
29. 6. II. J. Am. Chem. Soc. 1939, 61, 1242-1244.
30. 6 series. Chem. Ber. 1977, 110, 2106-2113.
31. 4. Pharm. Chem. J. 1983, 17, 665-669.
32. (a) Preparation of 71: Karminski-Zamola, G.; Dogan, J.; Bajic, M.; Blazevic, J.; Malesevic, M. Synthesis of some furyl- and thienylacrylates or diacrylates and acrylic acids by the palladium catalysed vinylation of substituted bromofurans and bromothiophenes. Heterocycles 1994, 38, 759-767.
33. (b) Hassan, J.; Sévignon, M.; Gozzi, C.; Schulz, E.; Lemaire, M. Aryl-aryl bond formation one century after the discovery of the Ullmann reaction. Chem. Rev. 2002, 102, 1359-1469.
34. Preparation of benzofurans: Chapleo, C. B.; Myers, P. L.; Butler, R. C. M.; Davis, J, A.; Doxey, J. C.; Higgins, S. D.; Myers, M.; Roach, A. G.; Smith, C. F. C.; Stillings, M. R.; Welbourn, A. P. α-Adrenoreceptor reagents. 2. Effects of modifications of the 1,4-benzodioxan ring system on α-adrenoreceptor activity. J. Med. Chem. 1984, 27, 570-576.
35. (a) Preparation of benzothiophenes: Bridges, A. J.; Lee, A.; Schwartz, C. E.; Towle, M. J.; Littlefield, B. A. The synthesis of three 4-substituted benzo[b]thiophene-2-carboxamidines as potent and selective inhibitors of urokinase. Bioorg. Med. Chem. 1993, 1, 403-410.
36. (b) Titus, R. L.; Titus, C. F. 2-Amino-3-(6-methoxybenzo[b]thien- 3-yl)propanoic acid. J. Heterocycl. Chem. 1973, 10, 679-681.
37. (c) Campaigne, E.; Rogers, R. B. Benzo[b]thiophene derivatives. XXI. On the proof of structure of the sulfur isostere of Psilocin. J. Het. Chem. 1973, 10, 963-966.
38. Preparation of indoles Marco, J. L. Improved preparation of N-propargyl-2-(5-benzyloxy-indolyl)methylamine. J. Heterocycl. Chem. 1998, 35, 475-476.
39. 2 receptor antagonists. 1. Bicyclo[2.2.1]heptane derivatives. J. Med. Chem. 2003, 46, 2436-2445.
40. (b) Chapman, N. B.; Clarke, K.; Saraf, S. D. Pharmacologically active benzo[b]thiophen derivatives. Part III. 2-Substituted compounds. J. Chem. Soc. C 1967, 731-735.
41. (c) Ogiso, A.; Kurabayashi, M.; Takahashi, S.; Mishima, H.; Woods, M. C. The structure and total synthesis of Futoenone, a constituent of Piper futokadzura. Chem. Pharm. Bull. 1970, 18, 105-114.
42. (d) Zaidlewicz, M.; Chechlowska, A.; Prewysz-Kwinto, A.; Wojtczak, A. Enantioselective synthesis of 2- and 3-benzofuryl β-amino alcohols. Heterocyles 2000, 55, 569-577.
43. Boyd, P. D. W.; Lena, G.; Spicer, J. A. Ethyl 4-hydroxymethyl-2- methylpyridine-5-carboxylate. Acta Crystallogr., Sect. E 2008, 64, o883.
44. Maron, D. M.; Ames, B. N. Revised methods for the Salmonella mutagenicity test. Mutat. Res. 1983, 113, 173-215.
45. Trapani, J. A. Dual mechanisms of apoptosis induction by cytotoxic lymphocytes. Int. Rev. Cytol. 1998, 182, 111-192.